Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2025-01-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2024-0829.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850273780846297088 |
|---|---|
| author | Sung Hwan Lee Sun Young Yim Ji Hoon Kim Sunyoung S. Lee Ahmed O. Kaseb Ju-Seog Lee |
| author_facet | Sung Hwan Lee Sun Young Yim Ji Hoon Kim Sunyoung S. Lee Ahmed O. Kaseb Ju-Seog Lee |
| author_sort | Sung Hwan Lee |
| collection | DOAJ |
| format | Article |
| id | doaj-art-ff0b73c6f7dd4926a5a512dcfe48dcb1 |
| institution | OA Journals |
| issn | 2287-2728 2287-285X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj-art-ff0b73c6f7dd4926a5a512dcfe48dcb12025-08-20T01:51:21ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2025-01-01311e81e8310.3350/cmh.2024.08292055Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”Sung Hwan Lee0Sun Young Yim1Ji Hoon Kim2Sunyoung S. Lee3Ahmed O. Kaseb4Ju-Seog Lee5 Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAhttp://e-cmh.org/upload/pdf/cmh-2024-0829.pdfliver cancerhepatocellular carcinomaimmunotherapybiomarkers |
| spellingShingle | Sung Hwan Lee Sun Young Yim Ji Hoon Kim Sunyoung S. Lee Ahmed O. Kaseb Ju-Seog Lee Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial” Clinical and Molecular Hepatology liver cancer hepatocellular carcinoma immunotherapy biomarkers |
| title | Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial” |
| title_full | Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial” |
| title_fullStr | Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial” |
| title_full_unstemmed | Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial” |
| title_short | Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial” |
| title_sort | correspondence to editorial 1 on genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma insights from the imbrave150 trial |
| topic | liver cancer hepatocellular carcinoma immunotherapy biomarkers |
| url | http://e-cmh.org/upload/pdf/cmh-2024-0829.pdf |
| work_keys_str_mv | AT sunghwanlee correspondencetoeditorial1ongenomicbiomarkerstopredictresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinomainsightsfromtheimbrave150trial AT sunyoungyim correspondencetoeditorial1ongenomicbiomarkerstopredictresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinomainsightsfromtheimbrave150trial AT jihoonkim correspondencetoeditorial1ongenomicbiomarkerstopredictresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinomainsightsfromtheimbrave150trial AT sunyoungslee correspondencetoeditorial1ongenomicbiomarkerstopredictresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinomainsightsfromtheimbrave150trial AT ahmedokaseb correspondencetoeditorial1ongenomicbiomarkerstopredictresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinomainsightsfromtheimbrave150trial AT juseoglee correspondencetoeditorial1ongenomicbiomarkerstopredictresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinomainsightsfromtheimbrave150trial |